Healthway Medical Valuation
Is 5NG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 5NG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 5NG (SGD0.05) is trading below our estimate of fair value (SGD0.06)
Significantly Below Fair Value: 5NG is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 5NG?
Other financial metrics that can be useful for relative valuation.
| What is 5NG's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | S$213.17m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 7.1x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 5NG's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 14x | ||
QC7 Q & M Dental Group (Singapore) | 19.3x | 14.7% | S$222.4m |
5G3 TalkMed Group | 17.3x | n/a | S$557.2m |
1B1 HC Surgical Specialists | 9.3x | n/a | S$40.0m |
P8A Cordlife Group | 10x | n/a | S$37.2m |
5NG Healthway Medical | 24.5x | n/a | S$213.2m |
Price-To-Earnings vs Peers: 5NG is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the peer average (21.8x).
Price to Earnings Ratio vs Industry
How does 5NG's PE Ratio compare vs other companies in the Asian Healthcare Industry?
Price-To-Earnings vs Industry: 5NG is expensive based on its Price-To-Earnings Ratio (24.5x) compared to the Asian Healthcare industry average (23.8x).
Price to Earnings Ratio vs Fair Ratio
What is 5NG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 24.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 5NG's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.